文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气消化、代谢与肾脏急症

临床表型分析揭示危重型COVID-19患者糖皮质激素治疗与生存之间的异质性关联

Clinical phenotyping uncovers heterogeneous associations between corticosteroid treatment and survival in critically ill COVID-19 patients.
PubMed 文献 · Intensive Care Med · 2024-08-26
一句话结论在82个荷兰ICU的13,279例危重型COVID-19患者中识别出三种临床表型,ICU入住后第5天[2-9]开始、疗程5天[3-7]的糖皮质激素治疗与COVIDICU1和COVIDICU2表型90天死亡风险升高相关,与COVIDICU3表型无关。

该 multinational 研究对2020年2月至2022年2月荷兰82个ICU收治的13,279例COVID-19患者,用入住ICU 24小时内的21项临床参数进行共识k-means聚类,并在西班牙6225例ICU患者中重复验证,同时在荷兰和德国的三个ICU队列中进行纵向免疫学表征。共得出三种表型:COVIDICU1(43%,较年轻、APACHE评分最低、BMI最高、PaO2/FiO2最低,90天院内死亡率18%)、COVIDICU2(37%,BMI最低、较年长、APACHE评分和死亡率24%高于COVIDICU1)、COVIDICU3(20%,最年长、合并症最多、APACHE评分最高、急性肾损伤和代谢紊乱、死亡率47%,炎症反应最显著)。糖皮质激素治疗于ICU入住后第5天[2-9]开始、疗程5天[3-7],与COVIDICU1和COVIDICU2表型90天死亡风险升高相关(HR 1.59 [1.09-2.31],p=0.015;HR 1.79 [1.42-2.26],p<0.001),与COVIDICU3表型无关(HR 1.08 [0.76-1.54],p=0.654)。

要点

  • 在13,279例荷兰ICU COVID-19患者中识别出三种临床表型,90天院内死亡率分别为COVIDICU1 18%、COVIDICU2 24%、COVIDICU3 47%。
  • COVIDICU3表型(20%)为最年长、合并症最多、APACHE评分最高、伴急性肾损伤和代谢紊乱、炎症反应最显著者。
  • ICU入住后第5天[2-9]开始、疗程5天[3-7]的糖皮质激素治疗与COVIDICU1表型90天死亡风险升高相关(HR 1.59 [1.09-2.31],p=0.015)。
  • 同一糖皮质激素治疗方案与COVIDICU2表型90天死亡风险升高相关(HR 1.79 [1.42-2.26],p<0.001)。
  • 该糖皮质激素治疗方案与COVIDICU3表型90天死亡风险无关(HR 1.08 [0.76-1.54],p=0.654)。

适用人群与场景

  • 荷兰82个ICU于2020年2月至2022年2月收治的13,279例COVID-19患者,聚类参数取自入住ICU后24小时内。
  • 西班牙ICU于2020年2月至2021年12月收治的6225例COVID-19患者用于表型重复验证。
  • 荷兰和德国的三个COVID-19 ICU队列用于纵向免疫学表征。

诊断标准与关键阈值

  • 基于入住ICU 24小时内21项临床参数进行共识k-means聚类,得出COVIDICU1、COVIDICU2、COVIDICU3三种表型。
  • COVIDICU1(占43%):较年轻、APACHE评分最低、BMI最高、PaO2/FiO2最低,90天院内死亡率18%。
  • COVIDICU2(占37%):BMI最低、较COVIDICU1年长、APACHE评分和死亡率(24%)高于COVIDICU1。
  • COVIDICU3(占20%):最年长、合并症最多、APACHE评分最高、伴急性肾损伤和代谢紊乱,90天院内死亡率47%,炎症反应最显著。

处置流程与药物剂量

  • 糖皮质激素治疗于ICU入住后第5天[2-9]开始,疗程5天[3-7]。
  • 该糖皮质激素治疗方案在COVIDICU1表型中与90天死亡风险升高相关(HR 1.59 [1.09-2.31],p=0.015)。
  • 该糖皮质激素治疗方案在COVIDICU2表型中与90天死亡风险升高相关(HR 1.79 [1.42-2.26],p<0.001)。
  • 该糖皮质激素治疗方案在COVIDICU3表型中与90天死亡风险无关(HR 1.08 [0.76-1.54],p=0.654)。

研究设计与关键结果

  • 研究类型为多国队列研究,荷兰82个ICU纳入13,279例COVID-19患者,西班牙6225例ICU患者用于重复验证,荷兰和德国三个ICU队列用于纵向免疫学表征。
  • COVIDICU1表型占43%,为较年轻、APACHE评分最低、BMI最高、PaO2/FiO2最低者,90天院内死亡率18%。
  • COVIDICU2表型占37%,BMI最低、较COVIDICU1年长、APACHE评分更高,90天院内死亡率24%。
  • COVIDICU3表型占20%,为最年长、合并症最多、APACHE评分最高、伴急性肾损伤和代谢紊乱者,90天院内死亡率47%,炎症反应最显著。
  • 糖皮质激素于ICU入住后第5天[2-9]开始、疗程5天[3-7],与COVIDICU1表型90天死亡风险升高相关(HR 1.59 [1.09-2.31],p=0.015),与COVIDICU2表型90天死亡风险升高相关(HR 1.79 [1.42-2.26],p<0.001),与COVIDICU3表型无关(HR 1.08 [0.76-1.54],p=0.654)。

证据类型、等级与局限

  • 证据类型:多国队列研究,表型在荷兰82个ICU的13,279例患者中推导,并在西班牙6225例ICU患者中重复验证。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,危重型COVID-19患者存在三种临床表型,对晚期、短期糖皮质激素治疗的反应存在明显差异。
  • 作者认为,COVIDICU1和COVIDICU2表型患者接受ICU入住后第5天[2-9]开始、疗程5天[3-7]的糖皮质激素治疗与90天死亡风险升高相关。
  • 作者认为,COVIDICU3表型患者接受该糖皮质激素治疗方案与90天死亡风险无关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Disease heterogeneity in coronavirus disease 2019 (COVID-19) may render the current one-size-fits-all treatment approach suboptimal. We aimed to identify and immunologically characterize clinical phenotypes among critically ill COVID-19 patients, and to assess heterogeneity of corticosteroid treatment effect.

METHODS: We applied consensus k-means clustering on 21 clinical parameters obtained within 24 h after admission to the intensive care unit (ICU) from 13,279 COVID-19 patients admitted to 82 Dutch ICUs from February 2020 to February 2022. Derived phenotypes were reproduced in 6225 COVID-19 ICU patients from Spain (February 2020 to December 2021). Longitudinal immunological characterization was performed in three COVID-19 ICU cohorts from the Netherlands and Germany, and associations between corticosteroid treatment and survival were assessed across phenotypes.

RESULTS: We derived three phenotypes: COVIDICU1 (43% of patients) consisted of younger patients with the lowest Acute Physiology And Chronic Health Evaluation (APACHE) scores, highest body mass index (BMI), lowest PaO2/FiO2 ratio, and a 90-day in-hospital mortality rate of 18%. COVIDICU2 patients (37%) had the lowest BMI, were older and had higher APACHE scores and mortality rate (24%) than COVIDICU1. Patients with COVIDICU3 (20%) were the eldest with the most comorbidities, the highest APACHE scores, acute kidney injury and metabolic dysregulations, and the highest mortality rate (47%). These patients also displayed the most pronounced inflammatory response. Corticosteroid therapy started at day 5 [2-9] after ICU admission and administered for 5 [3-7] days was associated with an increased risk for 90-day mortality in patients with the COVIDICU1 and COVIDICU2 phenotypes (hazard ratio [HR] 1.59 [1.09-2.31], p = 0.015 and HR 1.79 [1.42-2.26], p < 0.001, respectively), but not in patients with the COVIDICU3 phenotype (HR 1.08 [0.76-1.54], p = 0.654).

CONCLUSION: Our multinational study identified three distinct clinical COVID-19 phenotypes, each exhibiting marked differences in demographic, clinical, and immunological features, and in the response to late and short-term corticosteroid treatment.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Bruse N, Motos A, van Amstel R, et al. Clinical phenotyping uncovers heterogeneous associations between corticosteroid treatment and survival in critically ill COVID-19 patients. Intensive Care Med. 2024. PMID: 39186112. doi:10.1007/s00134-024-07593-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。